Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

NCT00458978 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

NIH

Sponsor class

Conditions

Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Laryngeal Verrucous Carcinoma
Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Recurrent Oral Cavity Verrucous Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma
Recurrent Salivary Gland Carcinoma
Salivary Gland Squamous Cell Carcinoma
Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary
Stage IV Hypopharyngeal Squamous Cell Carcinoma
Stage IV Laryngeal Squamous Cell Carcinoma
Stage IV Laryngeal Verrucous Carcinoma
Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
Stage IV Major Salivary Gland Carcinoma
Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Stage IV Oral Cavity Verrucous Carcinoma
Stage IV Oropharyngeal Squamous Cell Carcinoma
Tongue Carcinoma
Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary

Interventions

DRUG: Cediranib Maleate
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)